Company

IASO Bio Partners with Shenzhen Longuide to Deploy LNP Technology Beyond Oncology – Broadening the Cell Therapy Innovator's Advanced Therapeutics Portfolio
CAR-TIASO Biotherapeutics

IASO Bio Partners with Shenzhen Longuide to Deploy LNP Technology Beyond Oncology – Broadening the Cell Therapy Innovator’s Advanced Therapeutics Portfolio

IASO Biotherapeutics (IASO Bio), a Chinese cell therapy innovator, announced a strategic partnership with Shenzhen Longuide Biopharma Corporation (Longuide), under which IASO Bio will leverage Longuide's lipid nanoparticle (LNP) technology…

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform

Shanghai Henlius Advances Anti‑IL1RAP Antibody HLX109 Toward First‑in‑Human Trial – Australian HREC Approval and TGA CTN Completed for Generalized Pustular Psoriasis

Shanghai Henlius Advances Anti‑IL1RAP Antibody HLX109 Toward First‑in‑Human Trial – Australian HREC Approval and TGA CTN Completed for Generalized Pustular Psoriasis

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Ascentage Pharma Highlights Hematology Advances at EHA 2025, Focus on Olverembatinib and APG-5918
Academic conferenceAscentage Pharma

Ascentage Pharma Highlights Hematology Advances at EHA 2025, Focus on Olverembatinib and APG-5918

Clover Biopharmaceuticals Terminates Adimmune Influenza Vaccine Pact Over Market Shifts
AdimmuneClover Biopharmaceuticals

Clover Biopharmaceuticals Terminates Adimmune Influenza Vaccine Pact Over Market Shifts

Fosun Pharma's Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment
Fosun PharmaceuticalHenlius Biotech

Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment

Thermo Fisher Mulls $4B Diagnostic Business Sale Amid Healthcare Sector Turbulence
NYSE: TMOThermo Fisher Scientific

Thermo Fisher Mulls $4B Diagnostic Business Sale Amid Healthcare Sector Turbulence

Show More